New hope to stop Treatment-Disrupting side effect in breast cancer patients
NCT ID NCT07198672
Summary
This study tests whether Herombopag tablets can prevent low platelet counts (thrombocytopenia) in HER2-positive breast cancer patients receiving T-DM1 therapy. Low platelets are a common side effect that can cause bleeding risks and force treatment delays. The research will involve 45 female participants to see if this preventive approach helps patients complete their cancer treatment without interruptions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.